Empirical combination prophylaxis prior to immunosuppression prior to immunosuppression may be considered in selected patients with substantial epidemiological risk, while periodic repetition in those with ongoing exposure should be individualized given the limited direct evidence supporting this strategy.
V. Cruz, L. D. de Azevedo Valadares, C. Machado et al.· Advances in Rheumatology· 0 citations
Background Patients with rheumatoid arthritis (RA) generally have elevated levels of rheumatoid factor (RF), which binds to the crystallizable fraction (Fc) of monoclonal antibodies, diminishing tumour necrosis factor inhibitor (TNFi) efficacy. We assessed clinical response to PEGylated, Fc-free certolizumab pegol (CZP...
A. Kakehasi, João Gabriel Leão Sperancini Amaral, Jéssica Martins Amaral et al.· Drugs in Context· 0 citations
The BNT162b2 vaccine was safe and immunogenic in adolescents with IMIDs, including those with high immunosuppression and comorbidities, showing similar responses to adults, which support vaccination in this vulnerable population and contribute to evidence-based recommendations.
C. Gadelha, Maria Teresa Terreri, A. Burian et al.· Pediatric Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.